In a notable move within the biotechnology sector, Mark E. Strome, who maintains a 10% ownership stake in Zivo Bioscience, Inc. (NASDAQ: ZIVO), has expanded his position through affiliated entities. On April 17, 2026, an acquisition of 100,000 shares of common stock was finalized, representing a total investment value of $200,000.
The transaction was conducted at a price of $2.00 per share. This entry point is particularly noteworthy when compared to the prevailing market conditions, as the current trading price of the stock stands at $1.20. The discrepancy highlights a purchase made well above recent market valuations. This comes during a period of significant downward pressure for ZIVO; the stock has experienced a 43% decline over the last week and a substantial 93% decrease over the course of the past year.
Transaction Structure and Ownership Details
The acquisition was performed indirectly via Strome Mezzanine Fund II, LP (SMF II) as part of a Securities Purchase Agreement with the issuer. The reporting structure for this transaction involves several interconnected entities. Mark E. Strome, who holds the position of President and CEO of Strome Group, Inc., is identified alongside Strome Investment Management, LP and Strome Group, Inc. as the "Reporting Persons." These parties are collectively linked through a chain of management: Strome Investment Management, LP serves as the general partner of SMF II, while Strome Group, Inc. acts as the general partner for Strome Investment Management, LP. Consequently, these entities may be viewed as sharing investment and voting power over the shares held by SMF II.
Following this latest transaction, the collective indirect holdings of the Reporting Persons in Zivo Bioscience common stock amount to 572,942 shares. It is important to note that the filing specifies that this report does not constitute an admission that the Reporting Persons are beneficial owners of any reported equity securities for the purposes of Section 16 of the Exchange Act.
Key Market Observations
- Premium Entry Point: The purchase at $2.00 per share, versus a market price of $1.20, suggests an acquisition at a valuation higher than current public trading levels.
- Concentrated Ownership: The transaction reinforces the position of a 10% owner, increasing the total shares held by the reporting group to over 572,000.
- Market Valuation Context: Zivo Bioscience currently maintains a market capitalization of $4.79 million.
Risk Factors and Financial Indicators
Investors monitoring this activity should consider several documented financial indicators and risks associated with the company:
- Financial Health: Analysis indicates that the company currently holds a "Weak" financial health score.
- Volatility and Price Trends: The equity has faced extreme volatility, evidenced by the 93% decline over the past year and a 43% drop in just one week.
- Valuation Discrepancy: While some analysis suggests the stock may appear undervalued at current levels, the company's low market cap and financial health score represent ongoing variables for the biotech sector.